Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP-64 randomized study in recurrent malignant glioma
jRCT2031240090Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Randomised, open-label trial of copper-64-diacetyl-bis(N4-methylthiosemicarbazone) in malignant glioma and glioma (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: overall survival. Started May 2024; status: recruiting.
02
Drugs
copper-64-diacetyl-bis(N4-methylthiosemicarbazone)
03
Conditions
malignant gliomaglioma
Beyond the preview
Go deeper on jRCT2031240090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240090.